Inclisiran (sodium)
Product Sizes
5 mg
£ POA
HY-132591A-5MG
1 mg
£ POA
HY-132591A-1MG
10 mg
£ POA
HY-132591A-10MG
100 mg
£ POA
HY-132591A-100MG
50 mg
£ POA
HY-132591A-50MG
25 mg
£ POA
HY-132591A-25MG
About this Product
- SKU:
- HY-132591A
- Additional Names:
- ALN-PCSsc (sodium)
- Extra Details:
- Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis; activates PPARγ; and reduces NLRP3; cleaved caspase-1; IL-1β; and IL-18. Inclisiran sodium has anti-inflammatory; lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD)[1][2][3].
- Molecular Weight:
- 16339.6 (free acid)
- Purity:
- 98.91
- References:
- [1]Constantine E Kosmas, et al. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential. Ther Clin Risk Manag. 2020 Oct 28;16:1031-1037.|[2]Kong N, et al. PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis. Ann Transl Med. 2022;10(22):1205. |[3]Wang Z, et al. Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264.7 macrophages via activating the PPARγ pathway. Autoimmunity. 2022 Jun;55(4):223-232.
- Research Area:
- Metabolic Disease; Cardiovascular Disease
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- -20[o]C (Powder; sealed storage; away from moisture)
- Type:
- Molecular Biology Reagents: Nucleic Acids
- Pathway:
- Epigenetics;Metabolic Enzyme/Protease
